222 related articles for article (PubMed ID: 32046)
21. Single-dose evaluation of a new enteric-coated aspirin preparation.
Paull P; Day R; Graham G; Champion D
Med J Aust; 1976 Apr; 1(17):617-9. PubMed ID: 933973
[TBL] [Abstract][Full Text] [Related]
22. Enteric-coated pelletized aspirin. Gastrointestinal blood loss and bioavailability.
Portek I; Graham G; Fleming A
Med J Aust; 1981 Jul; 2(1):39-40. PubMed ID: 6974303
[TBL] [Abstract][Full Text] [Related]
23. The absorption of acetylsalicylic acid from an enteric-coated formulation and the inhibition of thromboxane formation.
Anttila M; Kahela P; Uotila P
Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):88-92. PubMed ID: 3410591
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic Study of Enteric-Coated Sustained-Release Aspirin Tablets in Healthy Chinese Participants.
Cong D; Qi W; Liu X; Xu X; Dong L; Xue W; Li K
Drug Des Devel Ther; 2023; 17():2421-2429. PubMed ID: 37614377
[TBL] [Abstract][Full Text] [Related]
25. Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.
Makino C; Ninomiya N; Sakai H; Orita H; Okano A; Yabuki A
Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):409-14. PubMed ID: 16595936
[TBL] [Abstract][Full Text] [Related]
26. Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin.
Ali M; McDonald JW; Thiessen JJ; Coates PE
Stroke; 1980; 11(1):9-13. PubMed ID: 7355437
[TBL] [Abstract][Full Text] [Related]
27. The bioavailability of enteric-coated acetylsalicylic acid: a comparison with buffered ASA in rheumatoid arthritis II.
Canada AT; Little AH; Creighton EL
Curr Ther Res Clin Exp; 1976 May; 19(5):554-7. PubMed ID: 820521
[No Abstract] [Full Text] [Related]
28. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
Bode-Böger SM; Böger RH; Schubert M; Frölich JC
Eur J Clin Pharmacol; 1998; 54(9-10):707-14. PubMed ID: 9923572
[TBL] [Abstract][Full Text] [Related]
29. Aspirin.
Scopp IW; Roehrl PL
N Y J Dent; 1979; 49(7):218-20. PubMed ID: 287960
[No Abstract] [Full Text] [Related]
30. Absorption of quinidine from an enteric-coated preparation.
Fremstad D; Nilsen OG; Amlie J; Storstein L; Olsson B; Jacobsen S
Eur J Clin Pharmacol; 1979 Sep; 16(2):107-12. PubMed ID: 499306
[TBL] [Abstract][Full Text] [Related]
31. Erythromycin absorption in healthy volunteers from single and multiple doses of enteric-coated pellets and tablets.
Hovi T; Josefsson K; Renkonen OV
Eur J Clin Pharmacol; 1983; 25(2):271-3. PubMed ID: 6628511
[TBL] [Abstract][Full Text] [Related]
32. [Effect of formulation of enterosoluable preparations on the physiologic availability of the active principle. 1: Effect on the rate of liberation of acetylsalicylic acid from enteric tablets on absorption characteristics in vivo].
Delporte JP; Jaminet F
J Pharm Belg; 1975; 30(2):99-113. PubMed ID: 1206458
[No Abstract] [Full Text] [Related]
33. Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle).
Carrigan PJ; Brinker DR; Cavanaugh JH; Lamm JE; Cloyd JC
J Clin Pharmacol; 1990 Aug; 30(8):743-7. PubMed ID: 2119396
[TBL] [Abstract][Full Text] [Related]
34. Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets.
Al-Habet SM; Rogers HJ
Eur J Clin Pharmacol; 1989; 37(4):423-6. PubMed ID: 2598978
[TBL] [Abstract][Full Text] [Related]
35. Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.
Malmborg AS
J Antimicrob Chemother; 1979 Sep; 5(5):591-9. PubMed ID: 500517
[TBL] [Abstract][Full Text] [Related]
36. Bioavailability of acetylsalicylic acid and salicylic acid from rapid-and slow-release formulations, and in combination with dipyridamol.
Brantmark B; Wåhlin-Boll E; Melander A
Eur J Clin Pharmacol; 1982; 22(4):309-14. PubMed ID: 7106166
[TBL] [Abstract][Full Text] [Related]
37. Bioequivalence and food effect study of enteric-coated mesalazine tablets in healthy Chinese volunteers by HPLC-ESI-MS/MS.
Guo ZH; Deng Y; Cai HL; Li HD; Li ZH; Yan M; Zhang BK
Int J Clin Pharmacol Ther; 2016 Jun; 54(6):484-94. PubMed ID: 27049053
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet and suppository dosage form.
Norlander B; Gotthard R; Ström M
Aliment Pharmacol Ther; 1989 Aug; 3(4):333-42. PubMed ID: 2518847
[TBL] [Abstract][Full Text] [Related]
39. Influence of food on aspirin absorption from tablets and buffered solutions.
Mason WD; Winer N
J Pharm Sci; 1983 Jul; 72(7):819-21. PubMed ID: 6886992
[TBL] [Abstract][Full Text] [Related]
40. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
Miner PB; Fort JG; Zhang Y
Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
